Clik here to view.
Goodwin Publishes Biosimilars Patent Litigation Update, Biosimilars...
Goodwin announced today the release of its 2016 BPCIA Litigation Update and Thinking of Investing In a Biosimilars Product? The 2016 BPCIA Litigation Update recaps a busy year in the legal world of...
View ArticleClik here to view.
Update on IPR Estoppel
Law360 has published an article by contributing editors here at Big Molecule Watch. The article, titled “IPR Estoppel Takes Shape,” looks at recent cases that discuss the scope of estoppel stemming...
View ArticleClik here to view.
Merck v. Gnosis: Standard of Review of Factual Findings in IPRs
We post frequently about IPRs here on the blog, because they are an efficient and relatively quick way to get a decision on validity of the patents that cover drugs, biologic or otherwise. In Merck...
View ArticleClik here to view.
Section 337 Actions at the ITC: another forum for pharma and biosimilars...
With the growing volume of biosimilar and pharma litigation in district courts and before the PTAB, the U.S. International Trade Commission may emerge as another forum for patent holders against...
View ArticleClik here to view.
Big Molecule Watch editor Rob Cerwinski to speak at ACI Annual Biosimilars...
On June 12-14th, at the Intercontinental New York Times Square, industry leaders from both innovator and biosimilar companies will convene at ACI’s 8th Annual Summit on Biosimilars to discuss the...
View ArticleClik here to view.
Goodwin Webinar: TC Heartland’s Impact on Hatch-Waxman
On Thursday, June 15, 2017, at 12:30 PM EST, Goodwin will host a webinar discussing TC Heartland’s impact on where to bring Hatch-Waxman and biosimilars litigation. The Supreme Court’s decision in TC...
View ArticleClik here to view.
Goodwin Webinar: The Supreme Court’s Decision in Sandoz v. Amgen
On Wednesday, June 28, 2017, at 12:00 PM EST, Goodwin will host a webinar discussing the Supreme Court’s Decision in Sandoz v. Amgen. On June 12, the Supreme Court decided Sandoz v. Amgen, which...
View ArticleClik here to view.
Goodwin Webinar Reminder: The Supreme Court’s Decision in Sandoz v. Amgen
On Wednesday, June 28, 2017, at 12:00 PM EST, Goodwin will host a webinar discussing the Supreme Court’s Decision in Sandoz v. Amgen. On June 12, the Supreme Court decided Sandoz v. Amgen, which...
View ArticleClik here to view.
Big Molecule Watch Editor Elaine Blais to Present During IPO IP Chat Channel...
On Wednesday, July 12, 2017, Goodwin’s Elaine Blais will present as a featured speaker during the one-hour webinar, “Who Will ‘Dance’ Now? Biosimilars After Amgen v. Sandoz,” hosted by the IPO IP Chat...
View ArticleClik here to view.
Goodwin Named IP Firm of the Year at 2017 LMG Life Sciences Awards
Goodwin’s Intellectual Property and Life Sciences teams won three awards, and were shortlisted in 10 categories for over 10 awards, at the 2017 LMG Life Sciences Awards hosted in New York City on...
View ArticleClik here to view.
Article Regarding Citizen Petitions by Goodwin’s Scott Lassman
We post frequently about citizen petitions here on the blog. Since the 1970s, the citizen petition process has allowed individual persons or organizations to request that FDA take or not take certain...
View ArticleClik here to view.
Big Molecule Watch Team Shares Biosimilars Landscape 2018 at J.P. Morgan...
Goodwin and the Big Molecule Watch team are looking forward to participating in the 36th Annual J.P. Morgan Healthcare Conference, bringing together industry leaders from across the country. If you...
View ArticleClik here to view.
Article Regarding The 2018 Biosimilar Litigation Landscape by BMW Editors
As we frequently report here on the blog, there has been increasing activity in BPCIA litigation concerning a variety of proposed and marketed biosimilar products. The coming year is likely to bring...
View ArticleClik here to view.
Big Molecule Watch Team at J.P. Morgan Healthcare Conference
Goodwin and the Big Molecule Watch team are looking forward to participating in the 35th Annual J.P. Morgan Healthcare Conference, which brings together leaders from across the industry. If you will...
View ArticleClik here to view.
Goodwin Publishes Biosimilars Patent Litigation Update, Biosimilars...
Goodwin announced today the release of its 2016 BPCIA Litigation Update and Thinking of Investing In a Biosimilars Product? The 2016 BPCIA Litigation Update recaps a busy year in the legal world of...
View ArticleClik here to view.
Update on IPR Estoppel
Law360 has published an article by contributing editors here at Big Molecule Watch. The article, titled “IPR Estoppel Takes Shape,” looks at recent cases that discuss the scope of estoppel stemming...
View ArticleClik here to view.
Merck v. Gnosis: Standard of Review of Factual Findings in IPRs
We post frequently about IPRs here on the blog, because they are an efficient and relatively quick way to get a decision on validity of the patents that cover drugs, biologic or otherwise. In Merck...
View ArticleClik here to view.
Big Molecule Watch Team at J.P. Morgan Healthcare Conference
Goodwin and the Big Molecule Watch team are looking forward to participating in the 35th Annual J.P. Morgan Healthcare Conference, which brings together leaders from across the industry. If you will...
View ArticleClik here to view.
Goodwin Publishes Biosimilars Patent Litigation Update, Biosimilars...
Goodwin announced today the release of its 2016 BPCIA Litigation Update and Thinking of Investing In a Biosimilars Product? The 2016 BPCIA Litigation Update recaps a busy year in the legal world of...
View ArticleClik here to view.
Update on IPR Estoppel
Law360 has published an article by contributing editors here at Big Molecule Watch. The article, titled “IPR Estoppel Takes Shape,” looks at recent cases that discuss the scope of estoppel stemming...
View Article
